Protalix Biotherapeutics (AMEX:PLX): “Buy” Rating was Kept by Researchers at H.C. Wainwright; with PT of $3.

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Corporate Logo

Reiterated Protalix Biotherapeutics (AMEX:PLX) Rating.

After H.C. Wainwright’s $3 PT was shared with investors and clients on 19 March, Protalix Biotherapeutics (AMEX:PLX) would indicate 500.00 % upside potential.

PLX hit $0.4966 during the last trading session after $0.0034 change.Currently Protalix BioTherapeutics, Inc. is downtrending after 27.64% change in last March 20, 2018. PLX has also 327,711 shares volume. PLX underperformed by 32.01% the S&P 500.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally.The firm is valued at $73.68 million. The firm offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.Last it reported negative earnings. The Company’s product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis.

Another two news for Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) were recently brought out by: Nasdaq.com on March 20, 2019 with title “Caledonia Mining Corporation Plc Results for the Fourth Quarter and Year ended December 31, 2018 – Nasdaq”. The other Nasdaq.com‘s article was titled “Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call – Nasdaq” and brought out on March 13, 2019.

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.